J&J, Acutus And Boston Scientific Announce Plans For Pulsed Field AF-Ablation Technologies
Pulsed field ablation, which uses a controlled electrical field instead of focused heat or cold, has shown promise as a safer alternative to thermal and cryo approaches for atrial fibrillation ablation.
You may also be interested in...
The series E financing will support the ongoing US trial of Adagio’s iCLAS cardiac cryoablation system and development of Adagio's pulsed field cryoablation technology while the company continues to commercialize iCLAS outside the US.
Boston Scientific’s management believes the ongoing recovery of procedure volumes and new technology will allow it to show revenue growth in the fourth quarter.
Johnson & Johnson’s worldwide medical device revenues grew about 50% sequentially in the third quarter to $6.2bn.